As of June 2026, the FDA is in a public comment period on a proposal to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List
Sports-Nutrition Guidelines (ACSM Position Stand) Thomas DT, Erdman KA, Burke LM
For conditions like PCOS or chronic inflammation, the goal is not to hit a target weight and quit
The launch of ColonBroom GLP-1 Booster represents a strategic expansion from gut health into the broader metabolic support space, offering a plant-based tool for wellness-minded adults
Lean Mass Preservation: A critical aspect of profound weight reduction is ensuring that patients primarily lose fat mass rather than skeletal muscle tissue
This receptor also helps slow gastric emptying, ultimately reducing whats coming in throughout the day